Tanios S. Bekaii-Saab, MD, highlights the unmet needs in GI malignancies and discusses how interdisciplinary meetings, such as the 20th Annual Meeting of the International Society of Gastrointestinal Oncology, provide the framework for disseminating information and driving innovative advances.
Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.
Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.
In this first episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, provide an overview on multicancer early detection tests and the need for randomized clinical trials to further explore their use.
Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.
Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.
Morie A. Gertz, MD, discusses the limitations of the current Mayo Stage IV amyloidosis treatment landscape, the rationale for investigating birtamimab in this population, and the importance of raising awareness for the AFFIRM-AL trial.
Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.
Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.
Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.
Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.
Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).
Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.
Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.
Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma.
Karen S. Anderson, MD, PhD, discusses novel and emerging therapies, as well as potential future targets, for the treatment of patients with hormone receptor–positive breast cancer.
Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.
Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.
Karen S. Anderson, MD, PhD, discusses the evolution of antibody-drug conjugates in the treatment of different subgroups of patients with metastatic breast cancer.
Thomas M. Habermann, MD, discusses the evolving treatment landscape of mantle cell lymphoma.
Karen S. Anderson, MD, PhD, discusses emerging data and role for CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer, along with the growing use of antibody-drug conjugates across the breast cancer spectrum and updates in triple-negative breast cancer.
Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.
Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.
Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.
Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.
A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.
Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.
